Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research

Treatment of < em > BRAF < /em > -V600E mutant metastatic colorectal cancer: new insights and biomarkers
Expert Rev Anticancer Ther. 2023 Jul 23:1-10. doi: 10.1080/14737140.2023.2236794. Online ahead of print.ABSTRACTINTRODUCTION: The presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous ...
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Javier Ros Marta Rodr íguez-Castells Nadia Saoudi Iosune Baraibar Francesc Salva Josep Tabernero Elena Élez Source Type: research

Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
We describe key mechanisms of resistance to ICIs and emerging therapies that are being investigated for patients who develop progression on ICIs and platinum-based chemotherapy.EXPERT OPINION: Emerging agents in development have a variety of different mechanisms of action and will likely change standard of care for second-line therapy and beyond for patients with NSCLC without AGAs in the future.PMID:37486248 | DOI:10.1080/14737140.2023.2235895 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - July 24, 2023 Category: Cancer & Oncology Authors: Ticiana Leal Mark A Socinski Source Type: research